Optimising Patient Care with CYP2C19 Genotyping

Clopidogrel is a vital antiplatelet agent used widely in the UK to prevent atherothrombotic events. However, because clopidogrel is a prodrug, it requires enzymatic conversion by the CYP2C19 enzyme to become active. Genetic variants in the CYP2C19 gene can significantly reduce or even abolish this conversion, leaving patients with “intermediate” or “poor” metaboliser phenotypes at higher risk of recurrent strokes or heart attacks.

To address this, the Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has developed new clinical guidelines to help prescribers integrate pharmacogenetic testing into standard care.

Key Recommendations for Clinicians

The guideline advocates for universal testing: any patient about to be prescribed clopidogrel, regardless of the indication, should undergo pharmacogenetic testing to identify clinically relevant CYP2C19 variants.

The guidance covers three primary clinical areas:

• Cerebrovascular Disease: Testing should be performed following a diagnosis of TIA or ischaemic stroke. For those with loss-of-function alleles, alternative antiplatelet agents such as ticagrelor or aspirin/dipyridamole are recommended.
• Coronary Artery Disease (CAD): Testing is recommended for individuals in whom clopidogrel is considered, particularly those with high bleeding risks or those undergoing cardiac catheterisation. Alternatives like prasugrel or ticagrelor should be considered for intermediate or poor metabolisers.
• Peripheral Arterial Disease (PAD): While the evidence base is still growing, the guideline recommends modifying clopidogrel use based on genotype or considering alternative regimens like low-dose rivaroxaban combined with aspirin for high-risk patients.

Implementation and Innovation

Developed by a multidisciplinary committee including specialists from the University of Liverpool, the British Pharmacological Society, and NHS England, these guidelines are designed to fit seamlessly into existing NHS pathways.

The guideline suggests a laboratory turnaround time of five days or less, though it also supports the use of point-of-care testing to ensure results are available quickly enough to guide acute treatment decisions.